Coordinating Center, The Biostatistics Center, George Washington University, Rockville, Maryland 20852, USA.
Obesity (Silver Spring). 2006 Nov;14(11):2107-17. doi: 10.1038/oby.2006.246.
We report the effects of several different measures of body size at baseline on the subsequent development of diabetes. High levels of body fat predict the onset of diabetes, but this association has not been previously reported in a large multiethnic population of overweight or obese people with impaired glucose tolerance.
Height, weight, waist circumference, hip circumference, and skinfolds were measured at baseline in 3234 participants enrolled in a randomized clinical trial to treat individuals with impaired glucose tolerance with placebo, metformin, or a lifestyle modification program. Cox proportional hazards models were used to assess the effect of baseline body size variables on the development of diabetes.
Over an average of 3.2 years in both the placebo and lifestyle groups, baseline waist circumference had the highest or second highest R(2) value for predicting diabetes in both sexes. Cox hazard ratios per 1 standard deviation were 1.43 and 1.49 for men in the placebo or lifestyle groups, respectively, and 1.29 and 1.53 for women in the placebo and lifestyle groups, respectively, adjusted for age and self-reported race/ethnicity. The c-statistic from the receiver operating characteristic curves also favored the waist circumference in men and women in the lifestyle group and men in the placebo group. No components of body size were predictive in the metformin-treated group, and metformin compared with the placebo group was effective in preventing diabetes only in individuals with a BMI > or =35 kg/m(2) or a waist circumference > or =98.0 cm.
Large waist circumference was a better predictor of risk for developing diabetes than most other measures in the placebo and lifestyle groups. No baseline measure of body size or shape predicted risk of diabetes in the metformin-treated group.
我们报告了基线时几种不同身体尺寸测量指标对后续糖尿病发病的影响。高水平的体脂可预测糖尿病的发病,但此前在大量糖耐量受损的超重或肥胖多民族人群中尚未报道过这种关联。
在一项随机临床试验中,对3234名参与者进行了基线身高、体重、腰围、臀围和皮褶厚度测量,该试验旨在用安慰剂、二甲双胍或生活方式改善计划治疗糖耐量受损的个体。采用Cox比例风险模型评估基线身体尺寸变量对糖尿病发病的影响。
在安慰剂组和生活方式组平均3.2年的时间里,基线腰围在预测男女糖尿病方面具有最高或第二高的R²值。在安慰剂组或生活方式组中,男性每增加1个标准差的Cox风险比分别为1.43和1.49,在安慰剂组和生活方式组中,女性分别为1.29和1.53,并根据年龄和自我报告的种族/民族进行了调整。来自受试者工作特征曲线的c统计量也表明,生活方式组中的男性和女性以及安慰剂组中的男性,腰围的预测效果更佳。在二甲双胍治疗组中,身体尺寸的各组成部分均无预测作用,与安慰剂组相比,二甲双胍仅在体重指数≥35kg/m²或腰围≥98.0cm 的个体中对预防糖尿病有效。
在安慰剂组和生活方式组中,大腰围比大多数其他测量指标更能预测糖尿病发病风险。在二甲双胍治疗组中,没有基线身体尺寸或形状测量指标能预测糖尿病风险。